Every Child By Two’s online platforms have reached over 11 million people with evidence based vaccine messaging in 2016. As we look back at the record number of views and shares there have been on Shot of Prevention blog posts this past year, we’re especially grateful to our blog readers, contributors and subscribers.
Whether you have shared a post, shared your story, or shared your expertise, know that our growth and success would not have been possible without your support. Thanks to you, people are referencing our content before making important immunization decisions for themselves and their families. In these final days of 2016, we hope that you will revisit these top five posts from the past year and share them with others in your social networks. Together, we can continue to engage more people in these important immunization discussions.
In 1949, Judith contracted polio along with 42,000 other people in the U.S. Judith survived five months in the hospital and multiple surgeries, but sadly 2,720 people died from polio that year. As Judith bravely shares her story, she explains that it represents an inconvenient truth to people who are in denial about the risks of polio. She is continually shocked by people who refuse vaccines, who refuse to believe she ever suffered with polio, or who actually believe the polio vaccine is part of a government or “big pharma” conspiracy. By sharing Judith’s story we hope to encourage continued polio vaccination and support of polio eradication worldwide and applaud people like Judith who are courageous enough to speak out in support of vaccines. To read Judith’s story, click here.
Emily Stillman was pronounced brain-dead just 30 hours from the onset of a severe headache. What they though was a migraine turned out to be meningococcal disease. In this post Emily’s mother Alicia explains that although Emily received a meningococcal vaccine, the MCV4 vaccine she received only protected her against meningococcal serogroups A, C, W and Y. It did not protect her against serogroup B, which is what caused Emily’s death. Since Emily’s death, a MenB vaccine has been approved for use. However, most parents still don’t know it exists and therefore, most students are still not protected.
As the Director of The Emily Stillman Foundation, Alicia Stillman helps educate people about the importance of “complete and total” protection against all serogroups of meningococcal disease. This means ensuring that teens and young adults receive both meningococcal vaccines; the MCV4 vaccine that protects against serogroups A,C, W and Y, as well as a MenB vaccine series. To learn more about fully protecting our youth against meningococcal disease, read Alicia’s guest blog here.
Although the HPV vaccine is one of the most effective ways we have to prevent numerous types of cancer, it is still being grossly underutilized. As a result of persistent but inaccurate myths circulating on the internet, some parents are more fearful of the HPV vaccine than the human papillomavirus itself. This is causing them to refuse or delay HPV vaccination for their children.
In this popular blog post, we highlight ten critical facts that address the most common misconceptions about HPV infection and the vaccine that can help prevent this very common infection. To learn more, be sure to read the post here.
There are many misconceptions about hepatitis B and how the infection is transmitted. Because of this, many parents don’t consider their children to be at risk of infection and so they question the need for a hepatitis B vaccine at birth. In this post, the Prevent Cancer Foundation explains the connection between hepatitis B and liver cancer and discusses ways in which infants and children can unknowingly contract hepatitis B. Their Think About the Link™ education campaign suggests that vaccinating infants before they leave the hospital is a critical first step in protecting your newborn from a virus that can lead to cancer later in life. To learn more about Hepatitis B and the vaccine to prevent it, click here.
Back in the 1980’s, Barbara Loe Fisher claimed that the whole cell pertussis vaccine (DTP) was dangerous and causing too many adverse events. Her complaints prompted the development of the more purified (acellular) pertussis vaccines that we use today; DTaP for infants, and Tdap for adolescents and adults. While studies have shown that these newer vaccines are not as effective as the old whole cell pertussis vaccine, they are the best protections we have against the dangers of pertussis.
Unfortunately, those who need protection the most are those who are too young to be vaccinated. Infants are at high risk of severe complications from pertussis, to include hospitalization and death, but babies don’t begin receiving pertussis vaccine until two months of age. After newborn Calle Van Tornhout contracted pertussis from a hospital nurse at birth, she died at just 37 days of age. Callie’s death has had her home state of Indiana considering a bill that would mandate pertussis vaccination among health care workers. But Barbara Loe Fisher is opposed to that as well. To read more about the history of pertussis vaccines, click here.
If you have suggestions for topics you would like us to address in 2016, or you would like to contribute a guest post for publication, please email firstname.lastname@example.org.
Don’t miss any of our new posts. Subscribe to Shot of Prevention by clicking the link at the top right of this page. You can also “Like” our Vaccinate Your Family Facebook page to receive updates on important immunization news and join in our online discussions.
Thanks again for your continued support and best wishes for a happy and healthy new year!
Three times a year a specialized group of medical and public health experts meet to review scientific data related to vaccine safety and effectiveness. This group, known as the Advisory Committee on Immunization Practices (ACIP), has an enormous responsibility. They establish, update and continually evaluate all the vaccine recommendations that are made in the United States for infants, adolescents and adults. Health insurance coverage of vaccines is based on these recommendations and the ACIP guidelines are considered the gold standard among healthcare providers.
Last week, in their second meeting of 2016, the ACIP discussed cholera, meningococcal, hepatitis, influenza, RSV and HPV vaccines, as well as the safety of maternal Tdap immunization and the laboratory containment of Poliovirus Type 2.
Below you will find a recap of the highlights of the June 2016 ACIP meeting to help keep you informed of the latest ACIP recommendations and considerations.
The most significant and somewhat surprising decision that occurred during last week’s ACIP meeting was that the Committee voted in favor of an interim recommendation that live attenuated influenza vaccine (LAIV), also known as the nasal spray flu vaccine, should not be used during the 2016-2017 flu season.
The vote followed an extensive review of data investigating the effectiveness of the nasal spray flu vaccine over the past three flu seasons. The data showed vaccine effectiveness for nasal spray vaccine among children 2 through 17 years during 2015-2016 was only 3% effective (with a 95% Confidence Interval of -49-37%). In comparison, flu shots had a vaccine effectiveness estimate of 63% against any flu virus among children 2 through 17 years (with a 95% Confidence Interval of 52-72%). This estimate clearly indicates that while no protective benefit could be measured from the nasal spray vaccine in this past season, flu shots provided measurable protection in comparison.
The disappointing vaccine effectiveness data for the nasal spray vaccine during the 2015-2016 season follows two previous seasons (2013-2014 and 2014-2015) that also showed poor and/or lower than expected vaccine effectiveness for LAIV. (More information about past LAIV VE data is available here.)
While it’s disheartening to see data suggesting that the nasal spray flu vaccine did not work as well as expected, the data did suggest that flu shots did perform well and offered substantial protection against influenza this past season. Some patients prefer the nasal spray flu vaccine due to an aversion to needles and may be disappointed in this vote. However, the action taken by the ACIP emphasizes the important role they fill in continually measuring and evaluating vaccine effectiveness. Only after a thorough review of the latest scientific data and discussion among the Committee do they decide to alter vaccine recommendations to ensure that they are in the best interest of the public’s health.
ACIP continues to recommend annual flu vaccination, with either the inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) for everyone 6 months and older and the CDC expects that there should be no shortage of injectable vaccines. However, it should be noted that with the ACIP vote the nasal spray flu vaccine should not be used during the 2016-2017 season and therefore should not be offered by providers or clinics and will not be covered under the Vaccines For Children (VFC) program.
A vote was taken to recommend the vaccine for people traveling to high risk areas.
For more information about cholera visit the CDC travel page here and for up-to-date travel alerts that address various destinations and diseases, we recommend visiting Passport Health’s travel alerts here.
The first part of the discussion of meningococcal vaccines was a consideration of the data on the serogroup B vaccine Trumenba. This particular vaccine is currently administered on a three dose schedule, however Pfizer’s Dr. Laura York indicated during her presentation that the FDA has approved both a 2 and 3 dose schedule based on the data showing both schedules to be considered safe and effective. While immunity data suggests that the 3 dose schedule may confer slightly greater immunity over longer periods of time, the 2 dose schedule would be considered optimal in the case of an outbreak or when it is important to confer rapid immunity. The committee will be reviewing more data on the duration of immunity and the safety of a 2 dose versus 3 dose schedule at the October meeting, before a formal recommendation is made for persons at increased risk, for use during outbreaks or for all healthy adolescents. Read more…